This article is more than 5 years old. Information may no longer be current.
VIDEO: EMPA-REG, LEADER trial results produce ‘exciting time’ for diabetes care
Click Here to Manage Email Alerts
NEW ORLEANS — The results of the EMPA-REG Outcome study and the LEADER trial have expanded physicians’ armamentariums to be able to decrease patients with diabetes risks for cardiovascular disease, according to Amisha Wallia, MD, MS, of Northwestern Memorial Hospital.
In this video, Wallia discusses the results of the EMPA-REG trial – which demonstrated the use of empagliflozin (Jardiance; Boehringer Ingelheim, Eli Lilly) decreased risk for heart failure hospitalization or cardiovascular death – as well as the results of the LEADER trial – which demonstrated the use of liraglutide (Victoza, Novo Nordisk) reduced risk for cardiovascular death, nonfatal myocardial infarction and stroke.
“There was a decrease in microvascular disease in both trials and actually in both trials this was largely driven by the outcome of nephropathy as opposed to retinopathy, perhaps because there were few events related to eye disease,” Wallia told Endocrine Today. “It’s a really exciting time in diabetes care and specifically having different tools to be able to decrease our patients risk for cardiovascular disease.”